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INTRODUCTION
Cisplatin is one of the most effective chemotherapeutic agents
and is widely used in the treatment of a variety of pediatric and adult
solid tumors including osteosarcoma (OS), medulloblastoma, and
neuroblastoma. Cisplatin is a DNA-damaging agent that forms
cisplatin-DNA adducts and kills cells via several mechanisms,
including induction of apoptosis [1]. Resistance to cisplatin is
multifactorial and leads to poor response to chemotherapy and
treatment failure. Failure to induce apoptosis is believed to be one of
the major mechanisms underlying cisplatin resistance [2,3].
OS is the most common malignant bone tumor in children. The
introduction of chemotherapy in 1970s significantly increased the
long-term survival rate of OS from 15% to 70% [4]. However, 30–
40% of patients with OS relapse with current therapies. After
relapse, only approximately one-quarter of patients survive beyond
5 years [5]. In the past several years, only minor improvements have
been achieved by intensifying chemotherapy, frequently offset by
significantly increasing toxicity. Efforts at identifying new risk
factors for the stratification of OS treatment are ongoing [5–7].
Histological response after neoadjuvant chemotherapy assessed at
the time of definitive surgery is the only reliable marker that can
predict outcome [2,3,8]. Since cisplatin is one of the most effective
chemotherapeutic agents that has been uniformly used in front line
chemotherapy of OS, the poorer response to OS chemotherapy is
likely due, at least in part, to cisplatin resistance.
It has been shown that cisplatin can activate the mitogen-
activated protein kinase (MAPK) pathways, leading to apoptotic
cell death [9]. There are three major pathways of MAPKs: stress-
activated protein kinase (SPK)/c-Jun NH2-terminal kinase (JNK),
p38 MAPK, and extra-cellular signal-regulated kinase (ERK) [10].
The importance of MAPK activation in cellular response to cisplatin
has been gradually appreciated in recent years [11,12]. MAPKs
control cell proliferation, differentiation, and cell death. Their role
in response to cisplatin is complex and the response varies with the
type of cells as well as their proliferation and differentiation status
[11–14]. It is believed that MAPK activities are regulated through
reversible phosphorylation of both threonine and tyrosine residues
by upstream kinases, as well as by the members of MAPK
phosphatase (MKP) family, which can dephosphorylate both
phospho-threonine and phospho-tyrosine residues and inactivate
MAPKs [2,15]. Recent studies suggest that MKP-1, the founding
member of MKP family, plays an important role in the response of
cancer cells to chemotherapy, especially to cisplatin [11,14,16].
Therefore, further investigation is warranted to study the role of
MKP-1 in pediatric cancers including OS.
MATERIALS AND METHODS
Reagents
Cisplatin was the product of Sicor Pharmaceuticals (Irvine, CA).
Triptolide was purchased from Calbiochem (Darmstadt, Germany).
MKP-1 antibody was the product of Santa Crutz Biotechnology
(Santa Cruz, CA). Antibodies against total and phosphorylated JNK
(p-JNK) and PARP, were the products of Cell Signaling Technology
(Beverly, MA). Anti-actin antibody (AC-74) was purchased from
Sigma.
Cell Lines and Cell Cultures
The human OS cell line U2OS, M189 and P16T were as
previously described [17,18]. These cells were maintained in RPMI
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1640 medium containing 10% of fetal bovine serum (FBS)
(Hyclone, Logan, UT), and 1% penicillin–streptomycin (Invitrogen
Life Technologies, Carlsbad, CA) in a humidified atmosphere of
5% CO2 at 378C.
Polyacrylamide Gel Electrophoresis (PAGE) and
Western Blotting
Whole-cell lysates were prepared as described [14]. Cell lysates
(30–100 mg) were electorphoresed through 10–15% SDS–PAGE.
Following electrophoresis, separated proteins on gels were electro-
transfered to PVD membranes (Schleicher & Schuell, Inc., Keene,
NH). Non-specific binding was blocked with blocking buffer
containing 10% fat-free milk powder in Tris buffer saline (TBS) for
1 hr at room temperature, followed by incubation with primary
antibodies in blocking buffer with 5% of fat-free milk powder
overnight at 48C and room temperature for 1 hr. The membrane was
then washed three times with TBS, and incubated with secondary
antibody for 1 hr at room temperature and washed three times. The
bound antibody was detected using Chemilluminescence reagent
(Amersham Pharmacia Biotech, Piscataway, NJ) according to the
manufacturer’s protocol.
Isolation of RNA and Northern Blot Analysis
Total cellular RNA was purified using the Trizol reagent
(Invitrogen Life Technologies) according to the manufacturer’s
instructions. Total RNA was separated in a 1.5% formaldehyde
agarose gel and blotted to Hybond-Nþ membrane (Amersham
Pharmacia Biotech). The blots were hybridized with 32P labeled
human MKP-1 cDNA as described previously [14]. Radioactive
signals were analyzed by autoradiography.
SiRNA Assay
MKP-1 siRNA pooled oligonucleotides were purchased from
Darmacon Research (Lafayette, CO). Briefly, U2OS cells were plated
at 105 cells per well in 6-well plates and transfected with MKP-1
siRNA using Oligofectamine reagent (Invitrogen Life Technologies)
according to the manufacturer’s instruction and as described
previously [14]. siGlow, which is Lamin A siRNA, was used as a
non-target fluorescent control. The cells were harvested 48–72 hr
after transfection for examination of MKP-1 expression by Western
blot and determination of cisplatin sensitivity by MTT assays.
MTT Assays
MTT assays were performed as described previously [14].
Briefly, cells were treated with cisplatin at different concentrations
for various times. In the experiments involving the triptolide, cells
were pretreated with triptolide for 2 hr before the cisplatin
treatment. After incubation with MTT solution, acid isopropanol
was added to dissolve formazan crystals. Absorbance was measured
using a Vmax microplate reader (Molecular Devices, Sunnyvale,
CA) at 590 nm, and percentage of survival was calculated.
In Vitro Cytotoxicity Assay Using Annexin V/PI and
Flow-Count Fluorospheres
P16T and U2OS cells were incubated in the presence of 5 mg/ml
of cisplatin for 4, 16, 20, and 24 hr in 35 mm Petri dishes. The
experiment was designed to add the cisplatin at the different time
points so that the cells could be harvested and assayed at the
same time to minimize variation. At the end of treatment,
the cisplatin treated and control cells (with no drug added), which
served as a baseline control for spontaneous apoptosis, were
trypsinized and resuspended in medium. Apoptosis detection was
performed using the Apoptosis Annexin-V FITC Kit (Beckman
Coulter, Brea, CA) per manufacturer’s instruction and as previously
described [19,20]. Briefly, 50 ml of resuspended cells were
transferred to clean 12 75 culture tubes containing 50 ml of
annexin V FITC/PI reagent and incubated in the dark for 15 min.
At the end of incubation, an additional 0.4 ml 1X Binding
Buffer containing 2.5–5% by volume Flow-Count Fluorospheres
(Beckman Coulter) was added to each tube, vortexed and then
analyzed using a Coulter XL Flow Cytometer (Coulter, Miami, FL).
Early apoptotic events were based on the annexin V positive, PI
negative population.
Statistical Analysis
All data are expressed as the mean SEM. Statistical analyses
were done using Student’s t-test. The data are presented as the
mean SD, and P 0.05 was considered significant.
RESULTS
High MKP-1 Expressing OS Cells Are Relatively
More Resistant to Cisplatin
Three OS cell lines, P16T, M189 and U2OS, were analyzed
for their level of MKP-1 expression and cisplatin sensitivity
(Fig. 1A–D). U2OS cells, which expressed highest level of
MKP-1, were most resistant to cisplatin-induced cell death. On
the other hand, only minimal MKP-1 expression was detected in
P16T cells which were most sensitive to cisplatin-induced cell death
(Fig. 1A–D). The above association of high MKP-1 expression and
cisplatin resistance implies that MKP-1 could be an important
determinant of cisplatin resistance. Of note, the concentrations of
cisplatin used in Figure 1C were across the in vivo concentration
spectrum when 100 mg/m2 of cisplatin was administered to patients
as a 24-hr intravenous infusion [21,22]. Because higher concen-
trations of cisplatin are required for the siRNA assay and for
induction of JNK activation as previously reported [14], we also
used cisplatin at higher than clinically applicable concentrations for
24-hr MTT assays. Again, U2OS cells were more resistant to
cisplatin than P16T cells (Fig. 1D).
SiRNA Silencing of MKP-1 Increases Cisplatin
Sensitivity in OS
Since high MKP-1 expressing OS cells are relatively more resistant
to cisplatin, we hypothesize that decreasing MKP-1 expression will
render the cells less resistant. To test this hypothesis, the effect of MKP-
1 knock down by siRNA on cisplatin sensitivity was examined. U2OS
cells, which are relatively more resistant to cisplatin and express higher
levels of MKP-1, were transfected with MKP-1 siRNA (Fig. 2). The
results showed that transfection with MKP-1 siRNA significantly
inhibited MKP-1 expression, indicating the silencing effect of MKP-1
siRNA (Fig. 2A). As hypothesized, MKP-1 knock down significantly
increased the cisplatin-induced cytotoxicity (Fig. 2B). As knock down
of MKP-1 renders OS cells less resistant to cisplatin, it is likely that
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MKP-1 plays an important role in cisplatin resistance. Of note, to catch
the peak effect of transient MKP-1 knock down by siRNA, the 24-hr
MTT assay with cisplatin at higher than clinically applicable
concentrations was used in this experiment to demonstrate a significant
difference between the control and siRNA transfected cells.
Cisplatin-Induced Cell Death Is Associated
With Apoptosis
To further delineate the mechanisms of cisplatin-induced
cytotoxicity and cisplatin resistance in OS, we examined
PARP cleavage by Western blot and annexin V staining by flow
cytometry as previously described [19,20]. As shown in Figure 3A
and B, the increased percentage of annexin V positive/PI negative
cell population and increased PARP cleavage were observed
following cisplatin treatment. In addition, both PARP cleavage
and percentage of annexin V positive/PI negative cell population
were increased more robustly and earlier in the time course in
P16T cells compared to U2OS cells. These results suggest that
cisplatin-induced cell death is associated with apoptosis induction,
and the delay of apoptosis induction in U2OS cells is asso-
ciated with relative cisplatin resistance. Furthermore, increased
apoptosis in P16T cells is associated with increased cisplatin
sensitivity.
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 1. MKP-1 expression and cisplatin sensitivity in OS cell lines. A: MKP-1 expression in three OS cell lines as determined by Western blot. The
high level of MKP-1 expression was evident in U2OS cells, and only minimal MKP-1 expression was detected in P16T cells. Actin was a loading
control. B: MKP-1 expression determined by Northern blot. U2OS and P16T cells were treated with 50 mg/ml of cisplatin for 1, 2, 4, and 6 hr. MKP-1
expression was detected in U2OS, but not in P16T cells prior to and following cisplatin treatment. 18S and 28S were loading controls.
C,D: Cisplatin-induced cell death in OS cell lines. The OS cells were incubated in the presence of cisplatin for 72 hr (C) at indicated concentrations
across the pharmacologically achievable in vivo concentration spectrum. The cell survivals were determined by MTT assay. When OS cells were
treated with 1 mg/ml of cisplatin, almost all P16T cells were killed after 72 hr, but 74% of U2OS cells survived the treatment (C). U2OS cells were
also more resistant than P16T cells when the cells were incubated in the higher concentrations of cisplatin for 24 hr (D). [Color figure can be viewed
in the online issue, which is available at www.interscience.wiley.com.]
Fig. 2. The effect of MKP-1 knock down on cisplatin sensitivity in U2OS cells. U2OS cells were transfected with MKP-1 siRNA. Forty-eight and
72 hr after transfection, MKP-1 expression was determined by Western blot and cisplatin cytotoxicity measured by MTTassay. MKP-1 siRNA and
NT represent MKP-1 siRNA and non-target transfected cells respectively; Control represents U2OS cells without transfection. A: Significantly
decreased MKP-1 expression was observed at both 48 and 72 hr after transfection of MKP-1 siRNA. Actin was a loading control. B: Significantly
increased cisplatin induced cell death was observed in MKP-1 siRNA transfected cells. At 48 hr after siRNA transfection, the cells were treated with
6.25 and 12.5 mg/ml of cisplatin for 24 hr.
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Cisplatin Induces Apoptosis by Activating JNK
Pathways and Expression of MKP-1 Is Associated
With Delay of Both JNK Phosphorylation and
Apoptosis Induction
To determine the relationship between cisplatin-induced JNK
activation and cell death in OS, we evaluated the phosphorylation
status of JNK and cleavage of PARP in response to cisplatin
treatment in U2OS and P16T cells. Delay of JNK phosphorylation
as well as PARP cleavage was observed in U2OS cells when
compared to P16T cells (Fig. 4). This suggests that delayed JNK
activation is associated with delayed apoptosis induction and
relative resistance to cisplatin in U2OS cells.
Inhibition of MKP-1 Expression by Triptolide Enhances
Cisplatin-Induced Cell Death in OS Cells
Triptolide has been reported to inhibit MKP-1 expression in
immortalized murine alveolar macrophages and macrophage cell
line RAW 264.7 [23,24]. However, its effect on the MAPK
pathways in tumor cells has not been previously studied. We have
demonstrated that MKP-1 silencing by siRNA enhances cisplatin-
induced cell death and renders U2OS cells more sensitive to
cisplatin (Fig. 2). We expect that triptolide, by inhibiting MKP-1
expression, may enhance cisplatin-induced cell death in high MKP-
1-expressing OS cells. To this end, MKP-1 expression, prior to and
following triptolide treatment, in U2OS cells was examined. While
MKP-1 expression was evident before triptolide treatment in U2OS
cells, it became undetectable after 4 hr of treatment (Fig. 5A). This
indicates that triptolide is a potent MKP-1 inhibitor in OS cells. We
then compared cisplatin-induced cell death in the presence and
absence of triptolide. Indeed, significantly increased cytotoxicity
was observed with the combination of cisplatin and triptolide
compared to cisplatin alone (Fig. 5B). These findings again suggest
that MKP-1 inhibition may enhance cisplatin-induced cell death
in OS.
DISCUSSION
Cisplatin is effective against a variety of solid tumors including
OS, neuroblastoma, and medulloblastoma. One of the drawbacks of
cisplatin treatment is development of resistance. The mechanism
underlying this resistance is incompletely understood. In the current
study, we have chosen OS as a model to study cisplatin resistance
because of the important role cisplatin plays in the treatment of
OS. We showed that MKP-1 high-expressing U2OS cells are
relatively more resistant to cisplatin-induced cell death compared to
MKP-1 low-expressing P16T cells. The association of high MKP-1
expression and increased cisplatin resistance implies that MKP-1
could be an important determinant of cisplatin resistance. However,
since each cell line may have different genetic alterations that could
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 3. Cisplatin-induced apoptosis in OS cells: P16T and U2OS cells were treated with 5 mg/ml of cisplatin for the indicated time, and the cells
with no drug added (0 hr) served as controls. The total and cleaved PARP was determined by Western blot analysis, annexin V/PI staining
was assayed by flow cytometry. A: Increased cleavage of PARP is evident 8 hr following cisplatin treatment in P16T cells but not until 16 hr in U2OS
cells. B: Significantly increased percentage of annexin V positive/PI negative cell population was obvious 16 hr following cisplatin treatment in
P16T cells, but not until 20 hr in U2OS cells. In addition, the more robust increase in annexin V positive/PI negative cell population was observed in
P16T compared to U2OS cells.
Fig. 4. JNK activation and PARP cleavage following cisplatin
treatment. P16T and U2OS cells were treated with cisplatin at
50 mg/ml for 1, 2, and 4 hr. JNK phosphorylation (p-JNK) was
undetectable in both P16T and U2OS cells prior to cisplatin treatment,
but became evident at 2 hr after cisplatin treatment in P16T cells
followed by PARP cleavage at 4 hr. In U2OS cells, p-JNK was not
observed until 4 hr after cisplatin treatment and no PARP cleavage
detected. MKP-1 expression was detected throughout the course in
U2OS but not in P16T cells. p-JNK, cleaved PARP and MKP-1 were
determined by Western blot. CTRL was a loading control.
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also affect cisplatin sensitivity, the relationship of MKP-1
expression and cisplatin sensitivity in different cell lines may not
fully reflect the role of MKP-1 expression in cisplatin resistance. To
this end, MKP-1 siRNA silencing in U2OS cells was performed
to minimize the effect of other genetic variations on cisplatin
sensitivity. The results showed that MKP-1 knockdown sensitizes
OS cells to cisplatin-induced cell death. Furthermore, decreased
MKP-1 expression and increased cisplatin-induced cell death
was observed when the OS cells were pre-treated with triptolide, a
recently identified MKP-1 inhibitor. These data suggest that
high level of MKP-1 expression contributes to cisplatin resistance
of OS.
MKP-1 dephosphorylates JNK and negatively regulates its
activity [11,25]. Since JNK has been shown to be an important
mediator of cisplatin-mediated killing, it has been postulated that
inhibition of JNK activation is one of the mechanisms underlying
the MKP-1 mediated cisplatin resistance [25]. The results of current
study are in support of that hypothesis, as high MKP-1 expression in
U2OS cells is associated with delayed JNK activation and apoptosis
induction alone with decreased cytotoxicity induced by cisplatin.
We have used clinically applicable concentrations of cisplatin in
the current study to measure cisplatin-induced cell death and
apoptosis induction in order to mimic in vivo condition as much as
possible. However, no persistent JNK activation was observed when
the cells were treated with 5 mg/ml of cisplatin, therefore, a higher
concentration was used for these experiments as previously
described in the literature [14]. In order not to miss the peak effect
of transient knock down of MKP-1 expression in the siRNA assay,
higher concentrations of cisplatin were also used to demonstrate
difference in cisplatin-induced killing between the control and
transfected cells in a 24-hr MTT assay.
In summary, we have shown that high MKP-1 expressing OS
cells are more resistant to cisplatin and MKP-1 inhibition enhances
cisplatin-induced cell death. Therefore, MKP-1 could potentially be
used as a marker of cisplatin resistance, and the combination of
MKP-1 inhibitors and cisplatin could be a novel strategy to
overcome cisplatin resistance. The current study is focused on OS;
however, the result may have implication beyond OS based on the
broad application of cisplatin in the treatment of other pediatric and
adult solid tumors, such as neuroblastoma.
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